New drug combo aims to shrink tough colorectal tumors before surgery

NCT ID NCT03926338

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving the immunotherapy drug toripalimab, with or without the anti-inflammatory drug celecoxib, before surgery can improve outcomes for people with a specific type of colorectal cancer (dMMR/MSI-H). About 270 participants will receive the drugs for 12 weeks, then undergo surgery. The main goals are to see how many patients have no cancer cells left at surgery and how long they stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
toripalimab (an immunotherapy drug) and celecoxib (an anti-inflammatory drug)
What this could lead to
If successful, this could lead to a more effective pre-surgery treatment for a hard-to-treat form of colorectal cancer, potentially improving outcomes and reducing recurrence.
What could go wrong
This is an early-phase trial with a moderate number of participants. The combination may not work better than toripalimab alone, and side effects from immunotherapy or celecoxib are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, 510655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.